Spyglass Pharma (SGP) FDA Approvals $27.96 +0.25 (+0.89%) As of 03:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Spyglass Pharma's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Spyglass Pharma (SGP). Over the past two years, Spyglass Pharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Bimatoprost. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Bimatoprost FDA Regulatory Events Bimatoprost is a drug developed by Spyglass Pharma for the following indication: in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Results - October 19,2026Results Drug: BimatoprostAnnounced Date: October 19, 2026Indication: in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.AnnouncementSpyGlass Pharma, Inc. announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL System (BIM-IOL System) in patients with mild-to-moderate open angle glaucoma (OAG) or ocular hypertension (OHT) undergoing routine cataract surgery.Read AnnouncementPositive Results - March 9,2026Positive Results Phase 1/2Drug: BimatoprostAnnounced Date: March 9, 2026Indication: in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.AnnouncementSpyGlass Pharma, Inc.AI SummarySpyGlass Pharma reported positive 12‑month results for its Bimatoprost Drug Pad‑IOL System (BIM‑IOL) to treat elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension who also had cataracts. In a randomized Phase 1/2 study of 104 patients, two BIM‑IOL dose groups were compared with a standard monofocal IOL plus timolol drops. At 12 months, 97% of BIM‑IOL patients were off all topical IOP‑lowering therapy. Visual outcomes were strong: 100% achieved 20/32 or better best‑corrected distance visual acuity and the mean BCDVA was equivalent to 20/20. Overall safety was comparable to routine cataract surgery. SpyGlass has begun two registrational Phase 3 trials of the 78‑mcg dose and continues long‑term follow‑up and enrollment. The company plans a 505(b)(2) pathway toward regulatory submission. Its non‑bioerodible delivery platform can carry bimatoprost and other small molecules, offering a durable treatment option for front and back of the eye. Read Announcement Spyglass Pharma FDA Events - Frequently Asked Questions Has Spyglass Pharma received FDA approval? As of now, Spyglass Pharma (SGP) has not received any FDA approvals for its therapy in the last two years. What drugs has Spyglass Pharma submitted to the FDA? In the past two years, Spyglass Pharma (SGP) has reported FDA regulatory activity for Bimatoprost. What is the most recent FDA event for Spyglass Pharma? The most recent FDA-related event for Spyglass Pharma occurred on October 19, 2026, involving Bimatoprost. The update was categorized as "Results," with the company reporting: "SpyGlass Pharma, Inc. announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL System (BIM-IOL System) in patients with mild-to-moderate open angle glaucoma (OAG) or ocular hypertension (OHT) undergoing routine cataract surgery." What conditions do Spyglass Pharma's current drugs treat? Currently, Spyglass Pharma has one therapy (Bimatoprost) targeting the following condition: in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Arbutus Biopharma FDA EventsAcumen Pharmaceuticals FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsDiaMedica Therapeutics FDA EventsGilead Sciences FDA EventsSCYNEXIS FDA EventsSciSparc FDA EventsAbbVie FDA EventsMedtronic FDA EventsTeleflex FDA EventsAchieve Life Sciences FDA EventsBioCryst Pharmaceuticals FDA EventsHeartBeam FDA EventsCardiff Oncology FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Tarsus Pharmaceuticals FDA Events Supernus Pharmaceuticals FDA Events Liquidia FDA Events MBX Biosciences FDA Events HUTCHMED FDA Events Harmony Biosciences FDA Events Urogen Pharma FDA Events Trevi Therapeutics FDA Events ANI Pharmaceuticals FDA Events Ocular Therapeutix FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:SGP last updated on 10/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s Next Partnership: Buy This Stock NowElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyglass Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyglass Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Results - October 19,2026Results Drug: BimatoprostAnnounced Date: October 19, 2026Indication: in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.AnnouncementSpyGlass Pharma, Inc. announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL System (BIM-IOL System) in patients with mild-to-moderate open angle glaucoma (OAG) or ocular hypertension (OHT) undergoing routine cataract surgery.Read Announcement
Positive Results - March 9,2026Positive Results Phase 1/2Drug: BimatoprostAnnounced Date: March 9, 2026Indication: in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.AnnouncementSpyGlass Pharma, Inc.AI SummarySpyGlass Pharma reported positive 12‑month results for its Bimatoprost Drug Pad‑IOL System (BIM‑IOL) to treat elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension who also had cataracts. In a randomized Phase 1/2 study of 104 patients, two BIM‑IOL dose groups were compared with a standard monofocal IOL plus timolol drops. At 12 months, 97% of BIM‑IOL patients were off all topical IOP‑lowering therapy. Visual outcomes were strong: 100% achieved 20/32 or better best‑corrected distance visual acuity and the mean BCDVA was equivalent to 20/20. Overall safety was comparable to routine cataract surgery. SpyGlass has begun two registrational Phase 3 trials of the 78‑mcg dose and continues long‑term follow‑up and enrollment. The company plans a 505(b)(2) pathway toward regulatory submission. Its non‑bioerodible delivery platform can carry bimatoprost and other small molecules, offering a durable treatment option for front and back of the eye. Read Announcement
